Is MEI Pharma Stock a Good Investment?
MEI Pharma Investment Advice | MEIP |
- Examine MEI Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research MEI Pharma's leadership team and their track record. Good management can help MEI Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact MEI Pharma's business and its evolving consumer preferences.
- Compare MEI Pharma's performance and market position to its competitors. Analyze how MEI Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if MEI Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about MEI Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in MEI Pharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if MEI Pharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine MEI Pharma Stock
Researching MEI Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 40.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.75. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MEI Pharma recorded a loss per share of 4.75. The entity last dividend was issued on the 16th of November 2023. The firm had 1:20 split on the 17th of April 2023.
To determine if MEI Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding MEI Pharma's research are outlined below:
| MEI Pharma had very high historical volatility over the last 90 days | |
| MEI Pharma has a very high chance of going through financial distress in the upcoming years | |
| MEI Pharma currently holds about 153.25 M in cash with (50.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15. |
MEI Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in MEI Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to MEI Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 24th of September 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
MEI Pharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.09 M.Basic technical analysis of MEI Stock
As of the 25th of June, MEI Pharma secures the mean deviation of 2.37, and Risk Adjusted Performance of 0.0688. In connection with fundamental indicators, the technical analysis model lets you check helpful technical drivers of MEI Pharma, as well as the relationship between them.MEI Pharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MEI Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on MEI Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MEI Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MEI Pharma's Outstanding Corporate Bonds
MEI Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MEI Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MEI bonds can be classified according to their maturity, which is the date when MEI Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MTB 465 27 JAN 26 Corp BondUS55279HAV24 | View | |
| MTB 47 27 JAN 28 Corp BondUS55279HAW07 | View | |
| US55279HAQ39 Corp BondUS55279HAQ39 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| US552704AF51 Corp BondUS552704AF51 | View |
Understand MEI Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing MEI Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0688 | |||
| Market Risk Adjusted Performance | 0.2442 | |||
| Mean Deviation | 2.37 | |||
| Semi Deviation | 2.77 | |||
| Downside Deviation | 3.27 | |||
| Coefficient Of Variation | 2569.21 | |||
| Standard Deviation | 3.14 | |||
| Variance | 9.88 | |||
| Information Ratio | 0.0234 | |||
| Jensen Alpha | 0.0937 | |||
| Total Risk Alpha | 0.0382 | |||
| Sortino Ratio | 0.0225 | |||
| Treynor Ratio | 0.2342 | |||
| Maximum Drawdown | 13.82 | |||
| Value At Risk | (4.41) | |||
| Potential Upside | 6.22 | |||
| Downside Variance | 10.71 | |||
| Semi Variance | 7.66 | |||
| Expected Short fall | (2.75) | |||
| Skewness | 0.393 | |||
| Kurtosis | 0.5284 |
| Risk Adjusted Performance | 0.0688 | |||
| Market Risk Adjusted Performance | 0.2442 | |||
| Mean Deviation | 2.37 | |||
| Semi Deviation | 2.77 | |||
| Downside Deviation | 3.27 | |||
| Coefficient Of Variation | 2569.21 | |||
| Standard Deviation | 3.14 | |||
| Variance | 9.88 | |||
| Information Ratio | 0.0234 | |||
| Jensen Alpha | 0.0937 | |||
| Total Risk Alpha | 0.0382 | |||
| Sortino Ratio | 0.0225 | |||
| Treynor Ratio | 0.2342 | |||
| Maximum Drawdown | 13.82 | |||
| Value At Risk | (4.41) | |||
| Potential Upside | 6.22 | |||
| Downside Variance | 10.71 | |||
| Semi Variance | 7.66 | |||
| Expected Short fall | (2.75) | |||
| Skewness | 0.393 | |||
| Kurtosis | 0.5284 |
Consider MEI Pharma's intraday indicators
MEI Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of MEI Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
MEI Pharma time-series forecasting models is one of many MEI Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary MEI Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
MEI Stock media impact
There is far too much social signal, news, headlines, and media speculation about MEI Pharma that are available to investors today. This information is accessible both publicly - through MEI Pharma's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of MEI-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of MEI Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of MEI Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to MEI Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive MEI Pharma alpha.
MEI Pharma Corporate Management
| BA Esq | COO Counsel | Profile | |
| Anne Frese | Chief Officer | Profile | |
| Eugene Park | VP Marketing | Profile | |
| Virginia Sankey | VP Fin | Profile | |
| JD Esq | Chief Officer | Profile | |
| Eric Deng | VP Operations | Profile |
Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.